Results 61 to 70 of about 4,399 (136)

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

Archives of Endocrinology and Metabolism
Objective Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the
Mira Siderova, Kiril Hristozov, Aleksandra Tsukeva   +2 more
doaj   +1 more source

Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

Clinical Case Reports, 2018
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or, Simona Fica   +5 more
doaj   +1 more source

Steroid Treatment Focused Management of Graves’ Ophthalmopathy

Acta Medica Bulgarica
Graves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis.
Condeng Y. H., Umar H., Aman A. M., Rasyid H., Bakri S., Iskandar H.   +5 more
doaj   +1 more source

Targeted immunotherapies for Graves’ thyroidal & orbital diseases

Frontiers in Immunology
BackgroundGraves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact.
Alan Chun Hong Lee, George J. Kahaly
doaj   +1 more source

Association between lipid profiles and Graves orbitopathy: A systematic review and meta analysis

Endocrine and Metabolic Science
Introduction: Graves orbitopathy (GO) is an autoimmune disorder affecting the tissues around the eyes, seen in 25–50 % of individuals with Graves disease (GD).
Nanny Natalia Mulyani Soetedjo, Louis Fabio Jonathan Jusni, Eric Ricardo Yonatan, Steven Alvianto, Nicolas Daniel Widjanarko, Hikmat Permana   +5 more
doaj   +1 more source

Psychiatric complications in Graves’ disease

European Thyroid Journal
Background: Mood disorders are common in Graves’ disease despite treatment. The pathogenic mechanisms involved are unknown and so is whether previous psychiatric disease influences these symptoms.
Mats Holmberg, Helge Malmgren, Peter F Berglund, Birgitta Johansson, Helena Filipsson Nyström   +4 more
doaj   +1 more source

Graves’ Orbitopathy

International Journal of Endocrinology, 2015
Yuji Hiromatsu, Jack R. Wall, George J. Kahaly, Hirohiko Kakizaki   +3 more
doaj   +1 more source

Mouse Model of Graves' Orbitopathy in Current Research and Future Perspectives. [PDF]

Medicina (Kaunas)
Lee GM, Jung WH, Kim Y, Oh MI, Jang SY.
europepmc   +1 more source

Sirolimus for the treatment of Graves' orbitopathy. [PDF]

Thyroid Res
Comi S, Sabini E, Cosentino G, Santini F, Marinò M.   +4 more
europepmc   +1 more source